← Back to Search

Other

DDP733 for Irritable Bowel Syndrome with Constipation

Phase 2 & 3
Waitlist Available
Research Sponsored by Dynogen Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Female from 18 to 65 years of age, inclusive
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial will study whether DDP733 is safe and effective for treating IBS-c in women. IBS-c is a gastrointestinal disorder.

Who is the study for?
This trial is for women aged 18-65 with IBS-c, experiencing abdominal pain or discomfort on at least 3 days per month for the last 3 months. Participants must not be pregnant, have serious diseases, psychiatric disorders, GI abnormalities/surgeries/infections, or use interfering substances like certain drugs, nicotine, or caffeine.Check my eligibility
What is being tested?
The study tests DDP733's safety and effectiveness against IBS-c in females compared to a placebo. Patients will report their symptoms using a daily diary via phone before being randomly assigned to either the drug or placebo group.See study design
What are the potential side effects?
While specific side effects of DDP733 are not listed here, common side effects from treatments targeting IBS-c may include nausea, headache, diarrhea or constipation changes if it behaves like other similar medications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a woman aged between 18 and 65.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Subject Global Assessment (SGA) of relief of IBS symptoms, collected weekly
Secondary outcome measures
Other secondary efficacy variables reflecting IBS symptoms include daily assessments of abdominal discomfort/pain; abdominal bloating, the number and consistency of stools, straining at defecation, and feeling of incomplete evacuation.
Weekly assessments of abdominal discomfort/pain, bowel habit, and satisfaction with bowel habit.

Find a Location

Who is running the clinical trial?

Dynogen PharmaceuticalsLead Sponsor
3 Previous Clinical Trials
208 Total Patients Enrolled
2 Trials studying Irritable Bowel Syndrome
178 Patients Enrolled for Irritable Bowel Syndrome
Dynogen Study Director, MDStudy DirectorDynogen Pharmaceuticals, Inc

Media Library

DDP733 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT00547469 — Phase 2 & 3
Irritable Bowel Syndrome Research Study Groups:
Irritable Bowel Syndrome Clinical Trial 2023: DDP733 Highlights & Side Effects. Trial Name: NCT00547469 — Phase 2 & 3
DDP733 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00547469 — Phase 2 & 3
Irritable Bowel Syndrome Patient Testimony for trial: Trial Name: NCT00547469 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are researcher still enrolling people in this experiment?

"Information available on clinicaltrials.gov suggests that this study is not looking for any more participants at the moment. This particular trial was first posted on October 1st, 2007 but the listing was last updated April 7th, 2008. There are 1547 other trials which are actively recruiting patients right now."

Answered by AI

In how many different medical clinics is this clinical study being run today?

"To make things easier for those who enroll, the 69 sites participating in this trial are located near major cities such as Seattle, Sherwood and Tucson. Additionally, there are other locations around these areas."

Answered by AI

Do you have to be a certain age to participate in this experiment?

"The age requirements to participate in this trial are that potential patients must be over 18 but under 65."

Answered by AI

For which patient population is this clinical trial designed?

"This study is looking for 360 patients that have irritable bowel syndrome and fit the following criteria: they must be female, between 18-65 years old, have experienced a change in their stool frequency or appearance, and be willing to use a phone-in information system to complete daily diary assessments."

Answered by AI

Who else is applying?

What state do they live in?
Washington
New York
Tennessee
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
1
2
0
3+
What site did they apply to?
Impact Clinical Trials
Medical Center for clinical research
Peters Medical Research dba Bethany Medical Center
Other

Why did patients apply to this trial?

This is the first trial I have applied for. I want to help myself and others with ibs. I.
PatientReceived no prior treatments
I use 3 different types of medications to have a bowel movement daily. It's 85% effective.
PatientReceived 1 prior treatment
I HAVE HAD IBS-C MY ENTIRE LIFE. I'VE EVEN BEEN HOSPITALIZED DUE TO ISCHEMIC CHOLITIS DUE TO IT.
PatientReceived 2+ prior treatments
Well because I've had this condition for years and it can be extremely bothersome particularly with the stomach and abdominal pain that's why I have to take bentyl off and on like I do!
PatientReceived no prior treatments

What questions have other patients asked about this trial?

How long do screenings take?
PatientReceived 2+ prior treatments
~21 spots leftby Apr 2025